ClinicalTrials.gg
CompletedNCT00044278Updated Jan 18, 2017

Pediatric Epilepsy Study in Subjects 1-24 Months

A Phase 2 interventional study of lamotrigine in Epilepsy, sponsored by GlaxoSmithKline. Completed at 70 sites in 15 countries. Open to participants aged 1 Month to 24 Months. Per ClinicalTrials.gov, last updated 2017-01-18.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
197
Allocation
Non-randomized
Ages
1 Month to 24 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing lamotrigine in Epilepsy — 2 open to participants now, 2 under way, none of them phase 3. Lamotrigine · Epilepsy.

Enrollment
8th of 36
197 · median 76
Started
2000
with 2 others
Phase 2
2 of 36
none open now
Registered
4th of 36
by date
Lead sponsor
19 of 36
GlaxoSmithKline

Among the 36 studies testing lamotrigine in Epilepsy, this one is the 8th largest by enrollment, is one of 3 that started in 2000, is one of 2 in phase 2, and was the 4th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 36 studies testing lamotrigine in Epilepsy are open now. Recruiting first, the newest first:

All 2 open studies →

About lamotrigine

Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 1 Month to 24 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing lamotrigine in Epilepsy, or all of them as a file.
02

Study summary

This study will evaluate the long-term safety of LAMICTAL(lamotrigine)in subjects with partial seizures previously enrolled in protocol LAM20006 and in subjects 1-24 months of age who have never received LAMICTAL(LAMICTAL-naive). For LAMICTAL-naive subjects, LAMICTAL will be added to the subject's current epilepsy medications.

03

Conditions studied

  • Epilepsy

Keywords

  • epilepsy
  • pediatric
  • partial seizures
04

Who can participate

Ages eligible
1 Month to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have completed the Open-Label Phase of protocol LAM20006 or meet criteria for LAMICTAL naive subjects as follows:
  • A confident diagnosis of epilepsy.
  • 4 or more partial seizures per month.
  • current treatment with 1 or 2 anti-epileptic drugs.

Exclusion criteria

Exclusion criteria:

  • Has seizures not related to epilepsy.
  • Has a surgically implanted and functioning vagal nerve stimulator.
  • Has previously been treated with lamotrigine.
  • Is currently taking felbamate, ACTH (adrenocorticotrophic hormone) or is on the ketogenic diet.
  • Use of experimental medication within 30 days of enrollment.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
197 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with overall, serious, drug-related treatment emergent adverse events and adverse events leading to premature study discontinuation

    Time frame: 43 Months

  2. Change from baseline in vital signs -heart rate (HR)

    Time frame: Up to 43 Months

  3. Change from baseline in vital signs - weight (WT)

    Time frame: Up to 43 months

  4. Change from baseline in vital signs - height (HT)

    Time frame: Up to 43 months

  5. Change from baseline in vital signs - head circumference (HC)

    Time frame: Up to 43 months

  6. Change from baseline in clinical chemistry parameters including Albumin and Total protein

    Time frame: Up to month 43

  7. Change from baseline in clinical chemistry parameters including alkaline phosphatase, Alanine transaminase (ALT), and Aspartate Aminotransferase (AST)

    Time frame: Up to 43 moths

  8. Change from baseline in clinical chemistry parameters including total bilirubin and creatinine

    Time frame: Up to 43 months

  9. Change from baseline in clinical chemistry parameters including glucose (glu), potassium (K), sodium (Na) and urea

    Time frame: Up to 43 months

  10. Change from baseline in hematological parameters including bands, basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and total white blood cells (WBC)

    Time frame: Up to 43 moths

  11. Change from baseline in Hemoglobin (Hb)

    Time frame: Up to 43 months

  12. Change from baseline in Mean corpuscular hemoglobin (MCH)

    Time frame: Up to 43 months

  13. Change from baseline in Mean corpuscular hemoglobin concentration (MCHC)

    Time frame: Up to 43 months

  14. Change from baseline in mean corpuscular volume (MCv)

    Time frame: Up to 43 months

  15. Change from baseline in red blood cells (RBC)

    Time frame: Up to 43 months

  16. Number of participants with treatment emergent neurological abnormalities

    Time frame: Up to 43 months

  17. Number of participants with treatment emergent clinically significant ECG abnormalities

    Time frame: Up to 43 months

  18. Number of participants with potentially clinically significant change in hematology parameters

    Time frame: Up to 43 months

  19. Number of participants with potentially clinically significant change in clinical chemistry parameters

    Time frame: Up to 43 months

  20. Number of participants with potentially clinically significant change in vital signs

    Time frame: Up to 43 months

Secondary outcomes

  1. Mean percentage change in seizure frequency between the Historical Baseline Phase and over the course of the 48-week Treatment Phase

    Time frame: Up to 48 Weeks

  2. Investigator's assessment of the participant's overall clinical status

    Time frame: Up to 43 months

  3. Mean Maximal plasma concentration (Cmax) in serum and saliva of Lamicital -naïve participants

    Time frame: Week 6

07

Study locations

70 sites
  • GSK Investigational Site
    Mobile, Alabama 36693, United States
  • GSK Investigational Site
    Tucson, Arizona 85712, United States
  • GSK Investigational Site
    Jonesboro, Arkansas 72401, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72202, United States
  • GSK Investigational Site
    Los Angeles, California 90027, United States
  • GSK Investigational Site
    Los Angeles, California 90095, United States
  • GSK Investigational Site
    Stanford, California 94305-5235, United States
  • GSK Investigational Site
    Denver, Colorado 80218, United States
  • GSK Investigational Site
    Washington, District of Columbia 20010, United States
  • GSK Investigational Site
    Jacksonville, Florida 32207, United States
  • GSK Investigational Site
    Miami, Florida 33155-3009, United States
  • GSK Investigational Site
    Orlando, Florida 32835, United States
  • GSK Investigational Site
    Tallahassee, Florida 32308, United States
  • GSK Investigational Site
    Tampa, Florida 33609, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Augusta, Georgia 30912, United States
  • GSK Investigational Site
    Lexington, Kentucky 40536-0284, United States
  • GSK Investigational Site
    St. Paul, Minnesota 55102-2383, United States
  • GSK Investigational Site
    Columbia, Missouri 65211, United States
  • GSK Investigational Site
    Kansas City, Missouri 64108, United States
  • GSK Investigational Site
    Cherry Hill, New Jersey 8034, United States
  • GSK Investigational Site
    Buffalo, New York 14222, United States
  • GSK Investigational Site
    Mineola, New York 11501, United States
  • GSK Investigational Site
    Syracuse, New York 13210, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27607, United States
  • GSK Investigational Site
    Akron, Ohio 44308-1062, United States
  • GSK Investigational Site
    Cleveland, Ohio 44106, United States
  • GSK Investigational Site
    Columbus, Ohio 43205, United States
  • GSK Investigational Site
    Portland, Oregon 97201-2884, United States
  • GSK Investigational Site
    Portland, Oregon 97201-2984, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15213-2583, United States
  • GSK Investigational Site
    Morristown, Tennessee 37813, United States
  • GSK Investigational Site
    Nashville, Tennessee 37212, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84113, United States
  • GSK Investigational Site
    Charlottesville, Virginia 22908, United States
  • GSK Investigational Site
    Norfolk, Virginia 23507, United States
  • GSK Investigational Site
    Richmond, Virginia 23298, United States
  • GSK Investigational Site
    Capital Federal, Buenos Aires 1181, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, 1425, Argentina
  • GSK Investigational Site
    Parkville, Melbourne, Victoria 3050, Australia
  • GSK Investigational Site
    Tartu, 51014, Estonia
  • GSK Investigational Site
    Reims Cedex, 51092, France
  • GSK Investigational Site
    Budapest, 1094, Hungary
  • GSK Investigational Site
    Debrecen, 4012, Hungary
  • GSK Investigational Site
    Miskolc, 3526, Hungary
  • GSK Investigational Site
    Pécs, 7623, Hungary
  • GSK Investigational Site
    Szeged, 6720, Hungary
  • GSK Investigational Site
    Napoli, Campania 80131, Italy
  • GSK Investigational Site
    Bologna, Emilia-Romagna 40138, Italy
  • GSK Investigational Site
    Mantova, Lombardia 46100, Italy
  • GSK Investigational Site
    Milano, Lombardia 20133, Italy
  • GSK Investigational Site
    Messina, Sicilia 98125, Italy
  • GSK Investigational Site
    Padova, Veneto 35128, Italy
  • GSK Investigational Site
    Riga, LV 1004, Latvia
  • GSK Investigational Site
    Beirut, 11072020, Lebanon
  • GSK Investigational Site
    Kaunas, LT-50009, Lithuania
  • GSK Investigational Site
    Groningen, 9713 GZ, Netherlands
  • GSK Investigational Site
    Rotterdam, 3015 GD, Netherlands
  • GSK Investigational Site
    Utrecht, 3584 EA, Netherlands
  • GSK Investigational Site
    Coimbra, 3000-075, Portugal
  • GSK Investigational Site
    Lisboa, 1150, Portugal
  • GSK Investigational Site
    Porto, 4099-001, Portugal
  • GSK Investigational Site
    SanJuan, 00936, Puerto Rico
  • GSK Investigational Site
    Bratislava, 833 40, Slovakia
  • GSK Investigational Site
    Presov, 080 01, Slovakia
  • GSK Investigational Site
    Ankara, Turkey
08

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2000, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2002
First posted
Aug 26, 2002
Start
Sep 2000
Primary completionActual
Jun 2006
CompletionActual
Jun 2006
Last update
Jan 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00044278
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 26, 2002
Start date
Sep 2000
Primary completion
Jun 2006
Completion
Jun 2006
Last update
Jan 18, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion